CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
增强血液系统恶性肿瘤中 CAR-T 细胞持久性的策略：从分子设计到临床优化
英文原题：Strategies to Enhance CAR-T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization.
查看英文原题
Strategies to Enhance CAR-T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法在治疗血液系统恶性肿瘤方面已展现出显著的临床疗效。然而，CAR-T 细胞在体内持久性有限仍是主要的治疗障碍，导致疾病复发。本综述探讨了当前增强CAR-T 细胞持久性的策略，重点关注CAR结构设计、基因编辑技术、体外培养优化、临床管理方法以及体内制备方面的最新进展。通过整合临床前研究和临床试验的见解，我们从技术角度全面分析了延长CAR-T 细胞持久性的方法，并讨论了未来的发展方向。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable clinical efficacy in treating hematological malignancies. Nevertheless, the limited persistence of CAR-T cells in vivo remains a major therapeutic hurdle, leading to disease relapse.
This review examines current strategies to enhance CAR-T cell durability, focusing on recent advances in CAR structural design, gene editing techniques, ex vivo culture optimization, clinical management approaches, and in vivo preparation. By integrating insights from preclinical studies and clinical trials, we provide a comprehensive analysis of methods to prolong CAR-T cell persistence from a technical perspective and discuss future directions.
论文信息
- 作者
- Yu M、Yang T、Ding S、Hu Y
- 单位
- Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- American journal of hematology2026 Feb
- 原文标识
- PubMed 41204883 · DOI 10.1002/ajh.70131